Review



prostate cancer tissue microarray tma  (Servicebio Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Servicebio Inc prostate cancer tissue microarray tma
    CHD1L is significantly upregulated in prostate cancer. ( A ) CHD1L expression in all prostate cancer ( n = 497) and normal prostate tissues ( n = 52) from the TCGA-PCa cohort. ( B ) Paired comparison of CHD1L expression between prostate cancer ( n = 52) and matched adjacent normal tissues ( n = 52) from the TCGA-PRAD cohort. ( C ) CHD1L expression in prostate cancer ( n = 13) and normal prostate tissues ( n = 8) from the GSE55945 dataset. ( D ) CHD1L expression in prostate cancer ( n = 57) and normal prostate tissues ( n = 90) from the GSE72220 dataset. ( E ) CHD1L expression in AR-independent ( n = 10) vs. AR-dependent ( n = 10) prostate cancer in the GSE2443 dataset. ( F ) Immunohistochemical staining(antibody HPA027789) of CHD1L in prostate cancer tissues from the Protein Atlas database. ( G ) Kaplan-Meier survival analysis showing disease-free survival (DFS) based on CHD1L expression, performed by the GEPIA2 web tool ( http://gepia2.cancer-pku.cn ) based on TCGA-PCa data. ( H ) Correlation of CHD1L with MKI67, a proliferation marker. ( I - J ) CHD1L expression in prostate cancer cell lines (Lncap, 22RV1, PC3, DU145) and normal RWPE1 cells. ( K - L ) CHD1L mRNA and protein levels in paired clinical prostate cancer specimens ( n = 6). ( M - N ) Five representative pairs and quantitative IHC scores from Tissue <t>microarray</t> <t>(TMA)-based</t> immunohistochemistry of paired prostate cancer ( n = 28) and adjacent normal samples ( n = 28). Error bars represent means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, ns, no significance; unpaired student’s t-test for 1 A, 1 C-1E; paired student’s t-test for 1B, 1 K and 1 N; one-way ANOVA for 1I
    Prostate Cancer Tissue Microarray Tma, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prostate+cancer+tissue+microarray/microarray+tissue/pmc12781402-52-1-9
    Average 86 stars, based on 1 article reviews
    prostate cancer tissue microarray tma - by Bioz Stars, 2026-09
    86/100 stars

    Images

    1) Product Images from "Targeting CHD1L suppresses prostate cancer progression via the FOXO3-PUMA axis"

    Article Title: Targeting CHD1L suppresses prostate cancer progression via the FOXO3-PUMA axis

    Journal: Journal of Translational Medicine

    doi: 10.1186/s12967-025-07529-5

    CHD1L is significantly upregulated in prostate cancer. ( A ) CHD1L expression in all prostate cancer ( n = 497) and normal prostate tissues ( n = 52) from the TCGA-PCa cohort. ( B ) Paired comparison of CHD1L expression between prostate cancer ( n = 52) and matched adjacent normal tissues ( n = 52) from the TCGA-PRAD cohort. ( C ) CHD1L expression in prostate cancer ( n = 13) and normal prostate tissues ( n = 8) from the GSE55945 dataset. ( D ) CHD1L expression in prostate cancer ( n = 57) and normal prostate tissues ( n = 90) from the GSE72220 dataset. ( E ) CHD1L expression in AR-independent ( n = 10) vs. AR-dependent ( n = 10) prostate cancer in the GSE2443 dataset. ( F ) Immunohistochemical staining(antibody HPA027789) of CHD1L in prostate cancer tissues from the Protein Atlas database. ( G ) Kaplan-Meier survival analysis showing disease-free survival (DFS) based on CHD1L expression, performed by the GEPIA2 web tool ( http://gepia2.cancer-pku.cn ) based on TCGA-PCa data. ( H ) Correlation of CHD1L with MKI67, a proliferation marker. ( I - J ) CHD1L expression in prostate cancer cell lines (Lncap, 22RV1, PC3, DU145) and normal RWPE1 cells. ( K - L ) CHD1L mRNA and protein levels in paired clinical prostate cancer specimens ( n = 6). ( M - N ) Five representative pairs and quantitative IHC scores from Tissue microarray (TMA)-based immunohistochemistry of paired prostate cancer ( n = 28) and adjacent normal samples ( n = 28). Error bars represent means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, ns, no significance; unpaired student’s t-test for 1 A, 1 C-1E; paired student’s t-test for 1B, 1 K and 1 N; one-way ANOVA for 1I
    Figure Legend Snippet: CHD1L is significantly upregulated in prostate cancer. ( A ) CHD1L expression in all prostate cancer ( n = 497) and normal prostate tissues ( n = 52) from the TCGA-PCa cohort. ( B ) Paired comparison of CHD1L expression between prostate cancer ( n = 52) and matched adjacent normal tissues ( n = 52) from the TCGA-PRAD cohort. ( C ) CHD1L expression in prostate cancer ( n = 13) and normal prostate tissues ( n = 8) from the GSE55945 dataset. ( D ) CHD1L expression in prostate cancer ( n = 57) and normal prostate tissues ( n = 90) from the GSE72220 dataset. ( E ) CHD1L expression in AR-independent ( n = 10) vs. AR-dependent ( n = 10) prostate cancer in the GSE2443 dataset. ( F ) Immunohistochemical staining(antibody HPA027789) of CHD1L in prostate cancer tissues from the Protein Atlas database. ( G ) Kaplan-Meier survival analysis showing disease-free survival (DFS) based on CHD1L expression, performed by the GEPIA2 web tool ( http://gepia2.cancer-pku.cn ) based on TCGA-PCa data. ( H ) Correlation of CHD1L with MKI67, a proliferation marker. ( I - J ) CHD1L expression in prostate cancer cell lines (Lncap, 22RV1, PC3, DU145) and normal RWPE1 cells. ( K - L ) CHD1L mRNA and protein levels in paired clinical prostate cancer specimens ( n = 6). ( M - N ) Five representative pairs and quantitative IHC scores from Tissue microarray (TMA)-based immunohistochemistry of paired prostate cancer ( n = 28) and adjacent normal samples ( n = 28). Error bars represent means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, ns, no significance; unpaired student’s t-test for 1 A, 1 C-1E; paired student’s t-test for 1B, 1 K and 1 N; one-way ANOVA for 1I

    Techniques Used: Expressing, Comparison, Immunohistochemical staining, Staining, Marker, Microarray, Immunohistochemistry

    Related Articles

    Microarray:

    Article Title: Targeting CHD1L suppresses prostate cancer progression via the FOXO3-PUMA axis
    Article Snippet: .. The prostate cancer tissue microarray (TMA) was obtained from Servicebio Technology (#PC-1601). .. Immunohistochemistry (IHC) was performed by Aifang Biotechnology Co., Ltd. using anti-CHD1L Rabbit mAb (Abcam, #ab197019).

    Article Title: Targeting CHD1L suppresses prostate cancer progression via the FOXO3-PUMA axis.
    Article Snippet: .. 135 Tissue Microarray and Immunohistochemistry 136 The prostate cancer tissue microarray (TMA) was obtained from Servicebio 137 Technology (#PC-1601). .. Immunohistochemistry (IHC) was performed by Aifang 138 Biotechnology Co., Ltd. using anti-CHD1L Rabbit mAb (Abcam, #ab197019).

    Article Title: SNCA inhibits breast cancer progression through TP53AIP1–p53-mediated mitochondrial apoptosis and suppression of cancer stemness
    Article Snippet: .. The BC 103 Jo urn al Pr e-p roo f 6 tissue microarray chips, which included both adjacent non-tumor tissues and primary 104 BC tissues, were purchased from Servicebio (Wuhan, China). ..

    Article Title: Neurogenic inducers inhibit the proliferation of pancreatic cancer by promoting tumor cell transdifferentiation.
    Article Snippet: .. Tissue microarray (TMA), immunohistochemistry (IHC) and immunofluorescent staining (IF) Clinical pancreatic tumor tissues obtained from surgical resections were fixed in 4% paraformaldehyde and embedded in paraffin before being sent to Wuhan Servicebio Technology for TMA fabrication and IHC staining. ..

    Article Title: Multiomics Reveals IL-17 Drives Epithelial Keratinization and Proliferation via EHF in Odontogenic Keratocysts
    Article Snippet: .. A tissue microarray comprising 24 OKC and 7 OM samples (Servicebio, Wuhan, China) was deparaffinized, rehydrated, antigen retrieved, and blocked as detailed in . .. Sections were incubated overnight at 4 °C with primary antibodies against KRT13, IL-17, and EHF (1:200; Proteintech, Wuhan, China).

    Article Title: Dysregulation of CircZNF79(5) Modulates YBX1 Stability and Selective Autophagy to Drive Hepatocellular Carcinoma Progression
    Article Snippet: .. Additionally, a tissue microarray containing 24 HCC samples (LWLT‐N‐48LV52) was purchased from Servicebio (Wuhan, China). .. Fluorescent in situ hybridization (FISH) assays for circZNF79(5) and IF assays for YBX1 and BRCC36 were performed by Servicebio.

    Article Title: Multiomics Reveals IL-17 Drives Epithelial Keratinization and Proliferation via EHF in Odontogenic Keratocysts.
    Article Snippet: .. A tissue microarray comprising 24 OKC and 7 OM samples (Servicebio, Wuhan, China) was deparaffinized, rehydrated, antigen retrieved, and blocked as detailed in Supplementary Table S15. .. Sections were incubated overnight at 4 ◦C with primary antibodies against KRT13, IL-17, and EHF (1:200; Proteintech, Wuhan, China).

    Article Title: Tumor cell derived CCL20 exacerbates the immunosuppressive microenvironment by recruiting CCR6 + Tregs in pancreatic cancer.
    Article Snippet: Pancreatic cancer has a dismal prognosis, largely due to resistance to all current therapeutic modalities, including prevailing immunotherapy.. Deciphering the mechanisms underlying the immunosuppressive tumor microenvironment is pivotal for developing effective therapeutic strategies.. In this study, we found that the expression of CCL20 is negatively correlated with the infiltration of CD8 T cells, and consistently, patients with higher CCL20 expression have a worse prognosis.

    Immunohistochemistry:

    Article Title: Targeting CHD1L suppresses prostate cancer progression via the FOXO3-PUMA axis.
    Article Snippet: .. 135 Tissue Microarray and Immunohistochemistry 136 The prostate cancer tissue microarray (TMA) was obtained from Servicebio 137 Technology (#PC-1601). .. Immunohistochemistry (IHC) was performed by Aifang 138 Biotechnology Co., Ltd. using anti-CHD1L Rabbit mAb (Abcam, #ab197019).

    Article Title: Neurogenic inducers inhibit the proliferation of pancreatic cancer by promoting tumor cell transdifferentiation.
    Article Snippet: .. Tissue microarray (TMA), immunohistochemistry (IHC) and immunofluorescent staining (IF) Clinical pancreatic tumor tissues obtained from surgical resections were fixed in 4% paraformaldehyde and embedded in paraffin before being sent to Wuhan Servicebio Technology for TMA fabrication and IHC staining. ..

    Article Title: Tumor cell derived CCL20 exacerbates the immunosuppressive microenvironment by recruiting CCR6 + Tregs in pancreatic cancer.
    Article Snippet: Pancreatic cancer has a dismal prognosis, largely due to resistance to all current therapeutic modalities, including prevailing immunotherapy.. Deciphering the mechanisms underlying the immunosuppressive tumor microenvironment is pivotal for developing effective therapeutic strategies.. In this study, we found that the expression of CCL20 is negatively correlated with the infiltration of CD8 T cells, and consistently, patients with higher CCL20 expression have a worse prognosis.

    Staining:

    Article Title: Neurogenic inducers inhibit the proliferation of pancreatic cancer by promoting tumor cell transdifferentiation.
    Article Snippet: .. Tissue microarray (TMA), immunohistochemistry (IHC) and immunofluorescent staining (IF) Clinical pancreatic tumor tissues obtained from surgical resections were fixed in 4% paraformaldehyde and embedded in paraffin before being sent to Wuhan Servicebio Technology for TMA fabrication and IHC staining. ..

    Construct:

    Article Title: Tumor cell derived CCL20 exacerbates the immunosuppressive microenvironment by recruiting CCR6 + Tregs in pancreatic cancer.
    Article Snippet: Pancreatic cancer has a dismal prognosis, largely due to resistance to all current therapeutic modalities, including prevailing immunotherapy.. Deciphering the mechanisms underlying the immunosuppressive tumor microenvironment is pivotal for developing effective therapeutic strategies.. In this study, we found that the expression of CCL20 is negatively correlated with the infiltration of CD8 T cells, and consistently, patients with higher CCL20 expression have a worse prognosis.



    Similar Products

    prostate cancer tissue microarray tma  (Servicebio Inc)
    86
    Servicebio Inc prostate cancer tissue microarray tma
    CHD1L is significantly upregulated in prostate cancer. ( A ) CHD1L expression in all prostate cancer ( n = 497) and normal prostate tissues ( n = 52) from the TCGA-PCa cohort. ( B ) Paired comparison of CHD1L expression between prostate cancer ( n = 52) and matched adjacent normal tissues ( n = 52) from the TCGA-PRAD cohort. ( C ) CHD1L expression in prostate cancer ( n = 13) and normal prostate tissues ( n = 8) from the GSE55945 dataset. ( D ) CHD1L expression in prostate cancer ( n = 57) and normal prostate tissues ( n = 90) from the GSE72220 dataset. ( E ) CHD1L expression in AR-independent ( n = 10) vs. AR-dependent ( n = 10) prostate cancer in the GSE2443 dataset. ( F ) Immunohistochemical staining(antibody HPA027789) of CHD1L in prostate cancer tissues from the Protein Atlas database. ( G ) Kaplan-Meier survival analysis showing disease-free survival (DFS) based on CHD1L expression, performed by the GEPIA2 web tool ( http://gepia2.cancer-pku.cn ) based on TCGA-PCa data. ( H ) Correlation of CHD1L with MKI67, a proliferation marker. ( I - J ) CHD1L expression in prostate cancer cell lines (Lncap, 22RV1, PC3, DU145) and normal RWPE1 cells. ( K - L ) CHD1L mRNA and protein levels in paired clinical prostate cancer specimens ( n = 6). ( M - N ) Five representative pairs and quantitative IHC scores from Tissue <t>microarray</t> <t>(TMA)-based</t> immunohistochemistry of paired prostate cancer ( n = 28) and adjacent normal samples ( n = 28). Error bars represent means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, ns, no significance; unpaired student’s t-test for 1 A, 1 C-1E; paired student’s t-test for 1B, 1 K and 1 N; one-way ANOVA for 1I
    Prostate Cancer Tissue Microarray Tma, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prostate+cancer+tissue+microarray/microarray+tissue/pmc12781402-52-1-9
    Average 86 stars, based on 1 article reviews
    prostate cancer tissue microarray tma - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    fda999u fda999w  (Novus Biologicals)
    90
    Novus Biologicals fda999u fda999w
    CHD1L is significantly upregulated in prostate cancer. ( A ) CHD1L expression in all prostate cancer ( n = 497) and normal prostate tissues ( n = 52) from the TCGA-PCa cohort. ( B ) Paired comparison of CHD1L expression between prostate cancer ( n = 52) and matched adjacent normal tissues ( n = 52) from the TCGA-PRAD cohort. ( C ) CHD1L expression in prostate cancer ( n = 13) and normal prostate tissues ( n = 8) from the GSE55945 dataset. ( D ) CHD1L expression in prostate cancer ( n = 57) and normal prostate tissues ( n = 90) from the GSE72220 dataset. ( E ) CHD1L expression in AR-independent ( n = 10) vs. AR-dependent ( n = 10) prostate cancer in the GSE2443 dataset. ( F ) Immunohistochemical staining(antibody HPA027789) of CHD1L in prostate cancer tissues from the Protein Atlas database. ( G ) Kaplan-Meier survival analysis showing disease-free survival (DFS) based on CHD1L expression, performed by the GEPIA2 web tool ( http://gepia2.cancer-pku.cn ) based on TCGA-PCa data. ( H ) Correlation of CHD1L with MKI67, a proliferation marker. ( I - J ) CHD1L expression in prostate cancer cell lines (Lncap, 22RV1, PC3, DU145) and normal RWPE1 cells. ( K - L ) CHD1L mRNA and protein levels in paired clinical prostate cancer specimens ( n = 6). ( M - N ) Five representative pairs and quantitative IHC scores from Tissue <t>microarray</t> <t>(TMA)-based</t> immunohistochemistry of paired prostate cancer ( n = 28) and adjacent normal samples ( n = 28). Error bars represent means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, ns, no significance; unpaired student’s t-test for 1 A, 1 C-1E; paired student’s t-test for 1B, 1 K and 1 N; one-way ANOVA for 1I
    Fda999u Fda999w, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prostate+cancer+tissue+microarray/Human+Prostate+Tissue+MicroArray+(Cancer)/pmc12767472-518-6-13
    Average 90 stars, based on 1 article reviews
    fda999u fda999w - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    nbp2  (Novus Biologicals)
    90
    Novus Biologicals nbp2
    CHD1L is significantly upregulated in prostate cancer. ( A ) CHD1L expression in all prostate cancer ( n = 497) and normal prostate tissues ( n = 52) from the TCGA-PCa cohort. ( B ) Paired comparison of CHD1L expression between prostate cancer ( n = 52) and matched adjacent normal tissues ( n = 52) from the TCGA-PRAD cohort. ( C ) CHD1L expression in prostate cancer ( n = 13) and normal prostate tissues ( n = 8) from the GSE55945 dataset. ( D ) CHD1L expression in prostate cancer ( n = 57) and normal prostate tissues ( n = 90) from the GSE72220 dataset. ( E ) CHD1L expression in AR-independent ( n = 10) vs. AR-dependent ( n = 10) prostate cancer in the GSE2443 dataset. ( F ) Immunohistochemical staining(antibody HPA027789) of CHD1L in prostate cancer tissues from the Protein Atlas database. ( G ) Kaplan-Meier survival analysis showing disease-free survival (DFS) based on CHD1L expression, performed by the GEPIA2 web tool ( http://gepia2.cancer-pku.cn ) based on TCGA-PCa data. ( H ) Correlation of CHD1L with MKI67, a proliferation marker. ( I - J ) CHD1L expression in prostate cancer cell lines (Lncap, 22RV1, PC3, DU145) and normal RWPE1 cells. ( K - L ) CHD1L mRNA and protein levels in paired clinical prostate cancer specimens ( n = 6). ( M - N ) Five representative pairs and quantitative IHC scores from Tissue <t>microarray</t> <t>(TMA)-based</t> immunohistochemistry of paired prostate cancer ( n = 28) and adjacent normal samples ( n = 28). Error bars represent means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, ns, no significance; unpaired student’s t-test for 1 A, 1 C-1E; paired student’s t-test for 1B, 1 K and 1 N; one-way ANOVA for 1I
    Nbp2, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prostate+cancer+tissue+microarray/Human+Prostate+Tissue+MicroArray+(Cancer)/pmc12767472-97-7-4
    Average 90 stars, based on 1 article reviews
    nbp2 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    case human prostate cancer tma  (Novus Biologicals)
    90
    Novus Biologicals case human prostate cancer tma
    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a <t>TMA</t> comprising <t>51</t> <t>prostate</t> tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.
    Case Human Prostate Cancer Tma, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prostate+cancer+tissue+microarray/Human+Prostate+Tissue+MicroArray+(Cancer)/bio_rxiv__2025__11__12__687981-134-5-13
    Average 90 stars, based on 1 article reviews
    case human prostate cancer tma - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    prostate cancer microarray  (Novus Biologicals)
    90
    Novus Biologicals prostate cancer microarray
    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a <t>TMA</t> comprising <t>51</t> <t>prostate</t> tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.
    Prostate Cancer Microarray, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prostate+cancer+tissue+microarray/Human+Prostate+Tissue+MicroArray+(Cancer)/pm41005308-793-47-52
    Average 90 stars, based on 1 article reviews
    prostate cancer microarray - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    human prostate cancer tissue microarray  (Servicebio Inc)
    86
    Servicebio Inc human prostate cancer tissue microarray
    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a <t>TMA</t> comprising <t>51</t> <t>prostate</t> tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.
    Human Prostate Cancer Tissue Microarray, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prostate+cancer+tissue+microarray/microarray+tissue/pmc12434036-92-1-13
    Average 86 stars, based on 1 article reviews
    human prostate cancer tissue microarray - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    prostate cancer tissue microarray  (Biomax Inc)
    90
    Biomax Inc prostate cancer tissue microarray
    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a <t>TMA</t> comprising <t>51</t> <t>prostate</t> tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.
    Prostate Cancer Tissue Microarray, supplied by Biomax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prostate+cancer+tissue+microarray/human+prostate+tissue+microarray+slides/pm39401629-58-1-15
    Average 90 stars, based on 1 article reviews
    prostate cancer tissue microarray - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    prostate cancer tissue microarray  (Novus Biologicals)
    90
    Novus Biologicals prostate cancer tissue microarray
    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a <t>TMA</t> comprising <t>51</t> <t>prostate</t> tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.
    Prostate Cancer Tissue Microarray, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/prostate+cancer+tissue+microarray/imh+303/us11891399-2772-1-19
    Average 90 stars, based on 1 article reviews
    prostate cancer tissue microarray - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    CHD1L is significantly upregulated in prostate cancer. ( A ) CHD1L expression in all prostate cancer ( n = 497) and normal prostate tissues ( n = 52) from the TCGA-PCa cohort. ( B ) Paired comparison of CHD1L expression between prostate cancer ( n = 52) and matched adjacent normal tissues ( n = 52) from the TCGA-PRAD cohort. ( C ) CHD1L expression in prostate cancer ( n = 13) and normal prostate tissues ( n = 8) from the GSE55945 dataset. ( D ) CHD1L expression in prostate cancer ( n = 57) and normal prostate tissues ( n = 90) from the GSE72220 dataset. ( E ) CHD1L expression in AR-independent ( n = 10) vs. AR-dependent ( n = 10) prostate cancer in the GSE2443 dataset. ( F ) Immunohistochemical staining(antibody HPA027789) of CHD1L in prostate cancer tissues from the Protein Atlas database. ( G ) Kaplan-Meier survival analysis showing disease-free survival (DFS) based on CHD1L expression, performed by the GEPIA2 web tool ( http://gepia2.cancer-pku.cn ) based on TCGA-PCa data. ( H ) Correlation of CHD1L with MKI67, a proliferation marker. ( I - J ) CHD1L expression in prostate cancer cell lines (Lncap, 22RV1, PC3, DU145) and normal RWPE1 cells. ( K - L ) CHD1L mRNA and protein levels in paired clinical prostate cancer specimens ( n = 6). ( M - N ) Five representative pairs and quantitative IHC scores from Tissue microarray (TMA)-based immunohistochemistry of paired prostate cancer ( n = 28) and adjacent normal samples ( n = 28). Error bars represent means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, ns, no significance; unpaired student’s t-test for 1 A, 1 C-1E; paired student’s t-test for 1B, 1 K and 1 N; one-way ANOVA for 1I

    Journal: Journal of Translational Medicine

    Article Title: Targeting CHD1L suppresses prostate cancer progression via the FOXO3-PUMA axis

    doi: 10.1186/s12967-025-07529-5

    Figure Lengend Snippet: CHD1L is significantly upregulated in prostate cancer. ( A ) CHD1L expression in all prostate cancer ( n = 497) and normal prostate tissues ( n = 52) from the TCGA-PCa cohort. ( B ) Paired comparison of CHD1L expression between prostate cancer ( n = 52) and matched adjacent normal tissues ( n = 52) from the TCGA-PRAD cohort. ( C ) CHD1L expression in prostate cancer ( n = 13) and normal prostate tissues ( n = 8) from the GSE55945 dataset. ( D ) CHD1L expression in prostate cancer ( n = 57) and normal prostate tissues ( n = 90) from the GSE72220 dataset. ( E ) CHD1L expression in AR-independent ( n = 10) vs. AR-dependent ( n = 10) prostate cancer in the GSE2443 dataset. ( F ) Immunohistochemical staining(antibody HPA027789) of CHD1L in prostate cancer tissues from the Protein Atlas database. ( G ) Kaplan-Meier survival analysis showing disease-free survival (DFS) based on CHD1L expression, performed by the GEPIA2 web tool ( http://gepia2.cancer-pku.cn ) based on TCGA-PCa data. ( H ) Correlation of CHD1L with MKI67, a proliferation marker. ( I - J ) CHD1L expression in prostate cancer cell lines (Lncap, 22RV1, PC3, DU145) and normal RWPE1 cells. ( K - L ) CHD1L mRNA and protein levels in paired clinical prostate cancer specimens ( n = 6). ( M - N ) Five representative pairs and quantitative IHC scores from Tissue microarray (TMA)-based immunohistochemistry of paired prostate cancer ( n = 28) and adjacent normal samples ( n = 28). Error bars represent means ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001, ns, no significance; unpaired student’s t-test for 1 A, 1 C-1E; paired student’s t-test for 1B, 1 K and 1 N; one-way ANOVA for 1I

    Article Snippet: The prostate cancer tissue microarray (TMA) was obtained from Servicebio Technology (#PC-1601).

    Techniques: Expressing, Comparison, Immunohistochemical staining, Staining, Marker, Microarray, Immunohistochemistry

    ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a TMA comprising 51 prostate tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.

    Journal: bioRxiv

    Article Title: Siglec-engaging immunosuppressive sialoglycans are upregulated in prostate cancer and are targetable to suppress bone metastasis

    doi: 10.1101/2025.11.12.687981

    Figure Lengend Snippet: ( A ) Analysis of Siglec-engaging sialoglycans using HYDRA immunohistochemistry in a TMA comprising 51 prostate tissue samples shows ligands for Siglec-3 (unpaired t test, p=0.0216), Siglec-7 (unpaired t test, p=0.0143) and Siglec-9 (unpaired t test, p=0.0271) are upregulated in prostate tumour tissue relative to normal prostate tissue. ( B ) Staining a previously published 96 case TMA [ , ] containing 17 normal prostate tissue samples and 79 samples of prostate tumour tissue showed that sialoglycan ligands for Siglec-3 (unpaired t test, p<0.001), Siglec-7 (unpaired t test, p<0.0001) and Siglec-9 (unpaired t test, p0.0171) are found at significantly higher levels in prostate tumours compared to normal prostate tissues. ( C ) HYDRA immunohistochemistry analysis of Siglec-3, -7 and -9 ligands in a previously published 200 case TMA [ , ] containing matched tumour and normal tissues from the same patient. Sialoglycan ligands recognised by Siglec-3 (paired t test, p<0.0001), Siglec-7 (paired t test, p=0.0003) and Siglec-9 (p<0.0001) are significantly increased in prostate cancer tissue relative to matched normal tissue from the same patient. Scale bar is 200□µm.

    Article Snippet: TMA cohort 1 : 40 case human prostate cancer TMA was purchased from Novus Bio (NBP2-30169).

    Techniques: Immunohistochemistry, Staining

    ( A ) HYDRA immunohistochemistry analysis of ligands for Siglec-3, Siglec-7, and Siglec-9 in untreated primary prostate tissue compared to metastatic castrate resistant cancer (CRPC) growing in bone suggests all three sialoglycan ligands are increased in treatment resistant metastatic tumours relative to untreated primary prostate cancer tissues (n=205, unpaired t tests, HYDRA-3 p <0.0001, HYDRA-7 p<0.0001, HYDRA-9 p<0.0001). Scale bar is 200□µm. ( B ) Analysis of Siglec-7 ligands in a TMA generated by the Movember Global Action Plan 1 Unique tissue microarray (GAP1-UTMA) project . HYDRA-7 immunohistochemistry shows Siglec-7 ligands are expressed at similar levels in untreated / hormone naïve primary prostate tumours compared to therapy resistant (CRPC) tissues (n=161, unpaired t test, p=0.0904). Scale bar is 200□µm. ( C ) HYDRA immunohistochemistry analysis of Siglec-7 ligands in a TMA containing primary prostate tissue and rapid autopsy tissue obtained from lethal visceral and bone metastatic tumours . HYDRA-7 Histoscores were significantly higher in lethal bone metastatic prostate tumours compared to unmatched primary prostate tumours (n=238, Welsh’s ANOVA test, p<0.0001). The levels of Siglec-7 ligands were significantly higher in prostate derived tumours growing in bone compared to matched visceral tumour tissue from the same patient (n=100, paired t test, p<0.0001). Scale bar is 200□µm. ( D ) HYDRA-7 immunohistochemistry analysis of Siglec-7 ligands in a 100-case prostate cancer TMA. Stratification of patients based on high and low Siglec-7 ligand levels shows patients with high HYDRA-7 levels (defined as the top 50 th percentile of expression) had significantly poorer survival rates compared to patients with low HYDRA-7 levels (defined as the bottom 50 th percentile of expression) (n=100, Kaplan-Meier regression model, p= 0.0041). Scale bar is 200□µm.

    Journal: bioRxiv

    Article Title: Siglec-engaging immunosuppressive sialoglycans are upregulated in prostate cancer and are targetable to suppress bone metastasis

    doi: 10.1101/2025.11.12.687981

    Figure Lengend Snippet: ( A ) HYDRA immunohistochemistry analysis of ligands for Siglec-3, Siglec-7, and Siglec-9 in untreated primary prostate tissue compared to metastatic castrate resistant cancer (CRPC) growing in bone suggests all three sialoglycan ligands are increased in treatment resistant metastatic tumours relative to untreated primary prostate cancer tissues (n=205, unpaired t tests, HYDRA-3 p <0.0001, HYDRA-7 p<0.0001, HYDRA-9 p<0.0001). Scale bar is 200□µm. ( B ) Analysis of Siglec-7 ligands in a TMA generated by the Movember Global Action Plan 1 Unique tissue microarray (GAP1-UTMA) project . HYDRA-7 immunohistochemistry shows Siglec-7 ligands are expressed at similar levels in untreated / hormone naïve primary prostate tumours compared to therapy resistant (CRPC) tissues (n=161, unpaired t test, p=0.0904). Scale bar is 200□µm. ( C ) HYDRA immunohistochemistry analysis of Siglec-7 ligands in a TMA containing primary prostate tissue and rapid autopsy tissue obtained from lethal visceral and bone metastatic tumours . HYDRA-7 Histoscores were significantly higher in lethal bone metastatic prostate tumours compared to unmatched primary prostate tumours (n=238, Welsh’s ANOVA test, p<0.0001). The levels of Siglec-7 ligands were significantly higher in prostate derived tumours growing in bone compared to matched visceral tumour tissue from the same patient (n=100, paired t test, p<0.0001). Scale bar is 200□µm. ( D ) HYDRA-7 immunohistochemistry analysis of Siglec-7 ligands in a 100-case prostate cancer TMA. Stratification of patients based on high and low Siglec-7 ligand levels shows patients with high HYDRA-7 levels (defined as the top 50 th percentile of expression) had significantly poorer survival rates compared to patients with low HYDRA-7 levels (defined as the bottom 50 th percentile of expression) (n=100, Kaplan-Meier regression model, p= 0.0041). Scale bar is 200□µm.

    Article Snippet: TMA cohort 1 : 40 case human prostate cancer TMA was purchased from Novus Bio (NBP2-30169).

    Techniques: Immunohistochemistry, Generated, Microarray, Derivative Assay, Expressing